Adeno-Associated Virus (AAV) Versus Immune Response [PDF]
Viruses, 2019 Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood⁻brain barrier (BBB), and host immune responses. These issues remain pertinent till today.
Joseph Rabinowitz +2 more
doaj +4 more sources
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Frontiers in Immunology, 2020 Recombinant adeno-associated virus (rAAV) vectors are one of the most promising in vivo gene delivery tools. Several features make rAAV vectors an ideal platform for gene transfer. However, the high homology with the parental wild-type virus, which often
Giuseppe Ronzitti +2 more
doaj +5 more sources
Adeno‐associated virus (AAV)-based gene therapy for glioblastoma [PDF]
Cancer Cell International, 2021 Glioblastoma (GBM) is the most common and malignant Grade IV primary craniocerebral tumor caused by glial cell carcinogenesis with an extremely poor median survival of 12–18 months.
Xin Xu +9 more
doaj +3 more sources
The Interplay between Adeno-Associated Virus and Its Helper Viruses [PDF]
Viruses, 2020 The adeno-associated virus (AAV) is a small, nonpathogenic parvovirus, which depends on helper factors to replicate. Those helper factors can be provided by coinfecting helper viruses such as adenoviruses, herpesviruses, or papillomaviruses.
Anita F. Meier +2 more
doaj +3 more sources
Herpes simplex virus co-infection facilitates rolling circle replication of the adeno-associated virus genome. [PDF]
PLoS Pathogens, 2021 Adeno-associated virus (AAV) genome replication only occurs in the presence of a co-infecting helper virus such as adenovirus type 5 (AdV5) or herpes simplex virus type 1 (HSV-1).
Anita Felicitas Meier +5 more
doaj +3 more sources
Advances in adeno-associated virus mediated gene therapy in tumors [PDF]
Jichu yixue yu linchuang, 2021 Adeno-associated virus (AAV) is a human parvovirus with defects and no disease.AAV vector, as an ideal carrier for the transduction of target genes, has certain advantages in long-term gene correction and gene therapy by transferring foreign bases into ...
YANG Xiao-juan, LI Zhen-hao, GOU Yuan-feng, HUO Xia-qin, PEI Ya-ping, LI Na, LIU Hui-ling
doaj +1 more source
Mass spectrometry friendly pH-gradient anion exchange chromatography for separation of full and empty Adeno-Associated Virus (AAV) capsids [PDF]
, 2023 The proportion of full and empty capsids represents a critical quality attribute of adeno-associated virus (AAV)-based therapeutics. In this study, pH-gradient anion exchange chromatography was utilized for the separation of full and empty capsid species.
Florian, Füssl +3 more
core +2 more sources
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy [PDF]
BioDrugs, 2017 There has been a resurgence in gene therapy efforts that is partly fueled by the identification and understanding of new gene delivery vectors. Adeno-associated virus (AAV) is a non-enveloped virus that can be engineered to deliver DNA to target cells, and has attracted a significant amount of attention in the field, especially in clinical-stage ...
Michael F. Naso +3 more
openaire +2 more sources
Adeno-associated virus (AAV) cell entry: structural insights [PDF]
Trends in Microbiology, 2022 Adeno-associated virus (AAV) is the leading vector in emerging treatments of inherited diseases. Higher transduction efficiencies and cellular specificity are required for broader clinical application, motivating investigations of virus-host molecular interactions during cell entry.
Nancy L. Meyer, Michael S. Chapman
openaire +2 more sources
Progress in the use of adeno-associated viral vectors for gene therapy [PDF]
, 2004 The development of safe and efficient gene transfer vectors is crucial for the success of gene therapy trials. A viral vector system promising to meet these requirements is based on the apathogenic adeno-associated virus (AAV-2), a member of the ...
Markus Braun-Falco +7 more
core +1 more source